Disease · MONDO_0016700

anaplastic ependymoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. anaplastic ependymoma. Diseases, record MONDO_0016700. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016700

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: anaplastic ependymoma; Open Targets
Open Targets ID: MONDO_0016700; Open Targets
Other names: WHO grade III ependymal neoplasm, WHO grade III ependymal tumor, WHO grade III ependymal tumour, anaplastic ependymal neoplasm, anaplastic ependymal tumor, anaplastic ependymal tumour, ependymoma, anaplastic, malignant, ependymoma, malignant, high-grade ependymoma, malignant ependymoma, undifferentiated ependymal neoplasm, undifferentiated ependymal tumor, undifferentiated ependymal tumour, undifferentiated ependymoma; Open Targets
Disease Ontology: DOID:5074; Disease Ontology
Disease Ontology: DOID:5889; Disease Ontology
NCI Thesaurus: C4049; NCI Thesaurus
Orphanet: ORPHA:251646; Orphanet
Highest stage of its drugs: Phase 2, for 1 of its 2 drugs, from ClinicalTrials.gov; Open Targets

Drugs2

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MARIZOMIB	CHEMBL371405	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
AXL-1717	CHEMBL283120	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets20

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
IGF1R	Insulin-like growth factor 1 receptor	1	Insulin-like growth factor I receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/3480	Drugs and targets
PSMA1	20S proteasome	1	20S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5682	Drugs and targets
PSMA2	20S proteasome	1	20S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5683	Drugs and targets
PSMA3	20S proteasome	1	20S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5684	Drugs and targets
PSMA4	20S proteasome	1	20S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5685	Drugs and targets
PSMA5	20S proteasome	1	20S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5686	Drugs and targets
PSMA6	20S proteasome	1	20S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5687	Drugs and targets
PSMA7	20S proteasome	1	20S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5688	Drugs and targets
PSMA8	20S proteasome	1	20S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/143471	Drugs and targets
PSMB1	20S proteasome	1	20S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5689	Drugs and targets

1 to 10 of 20

See all 20 targets

Trials2

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01721577	Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas	Phase 1/2	10	2023-05-22	Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Anaplastic Ependymoma	AXL-1717	Its record names the disease	ClinicalTrials.gov
NCT03727841	Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma	Phase 2	4	2021-11-30	Anaplastic Ependymoma, Ependymoma, Ependymomas	MARIZOMIB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
AXL1717, 400mg Initial Dose vs AXL1717, 300mg Initial Dose: Phase I Subjects - Imaging Evidence of Response.	0 of 2	5 of 7	9	NCT01721577	Trial comparisons
1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)	3 of 3	1 of 1	4	NCT03727841	Trial comparisons
1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: Number of Participants That Are Progression-free at 6 Months Time Point After Initiation of Treatment	1 of 3	0 of 1	4	NCT03727841	Trial comparisons
1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: Number of Participants That Have Progressive Disease After 6 Months	1 of 3	0 of 1	4	NCT03727841	Trial comparisons
1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: Number of Participants With 12-month Progression-free Survival (PFS12)	0 of 3	0 of 1	4	NCT03727841	Trial comparisons
1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: Number of Participants Assessed Using the Response Assessment in Neuro-oncology Criteria (RANO) for Complete Response (CR) + Partial Response (PR)	0 of 3	0 of 1	4	NCT03727841	Trial comparisons
1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: deaths from any cause	0 of 3	0 of 1	4	NCT03727841	Trial comparisons
1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: serious adverse events	1 of 3	0 of 1	4	NCT03727841	Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016700

GET https://conductscience.org/api/diseases/v1/MONDO_0016700/drugs

API reference For AI assistants